Anticoagulation and protamine

Surgical approach (where relevant)

Most relevant to: cardiac surgery with CPB, major vascular surgery (e.g. carotid endarterectomy, EVAR/open AAA), interventional radiology/cath lab procedures requiring systemic heparinisation
Typical steps (CPB context)
- Systemic UFH given before cannulation; target ACT achieved before aortic/venous cannulation
- Heparin supplementation during CPB guided by ACT/anti-Xa/heparin concentration (institution dependent)
- At end of CPB: rewarming, separation from bypass, surgical haemostasis; then protamine administered to reverse heparin
- Persistent bleeding prompts: surgical re-exploration of field, correction of coagulopathy (platelets, fibrinogen, PCC/FFP), consideration of residual heparin/rebound
Typical steps (vascular/non-CPB context)
- IV UFH bolus prior to cross-clamping or endovascular instrumentation; sometimes repeated boluses/infusion
- Reversal with protamine may be partial or omitted depending on bleeding/thrombosis balance (e.g. carotid surgery often partial reversal; endovascular varies)

Anaesthetic management (procedure context dependent)

Type of anaesthesia
- Cardiac surgery/CPB: GA with invasive monitoring; TEE commonly
- Major vascular: usually GA; selected cases regional (e.g. carotid under cervical plexus block) but systemic heparinisation influences neuraxial decisions
Airway
- CPB/major vascular: ETT standard; SGA generally inappropriate
Duration
- Highly variable: endovascular 1–3 h; open vascular 2–6 h; cardiac with CPB 3–6+ h
Pain
- Cardiac sternotomy/open vascular: moderate–severe; endovascular: mild–moderate
Key anaesthetic priorities around anticoagulation/reversal
- Baseline coagulation/platelets/fibrinogen; anticipate dilutional coagulopathy, hypothermia, acidosis, thrombocytopenia/platelet dysfunction (esp. CPB)
- Monitoring: ACT/anti-Xa/heparin concentration as per local protocol; interpret in context (hypothermia, haemodilution, thrombocytopenia affect ACT)
- Protamine administration: slow IV, readiness for anaphylaxis, pulmonary hypertension, RV failure, systemic hypotension; have vasopressors/inotropes and resuscitation drugs prepared
- Post-reversal bleeding: distinguish surgical vs coagulopathic; consider residual heparin/rebound; use targeted blood products guided by viscoelastic testing if available

Core pharmacology: Unfractionated heparin (UFH)

Mechanism: binds antithrombin (AT) → accelerates inhibition of thrombin (IIa) and factor Xa (also IXa, XIa, XIIa). Requires AT presence.
Pharmacokinetics: IV onset immediate; non-linear dose–response due to binding to plasma proteins/endothelium/macrophages. Clearance partly saturable; half-life increases with dose (approx 30–90 min).
Monitoring
- Therapeutic anticoagulation (medical): aPTT (reflects intrinsic/common pathways) or anti-Xa (more direct).
- High-dose intraoperative/CPB: ACT (bedside). Influenced by hypothermia, haemodilution, thrombocytopenia, factor deficiency, aprotinin (historical), lupus anticoagulant.
- Heparin concentration assays (e.g. protamine titration systems) used in some cardiac centres to guide dosing/reversal.
Adverse effects
- Bleeding; osteoporosis (long-term); hyperkalaemia (hypoaldosteronism); elevated transaminases.
- HIT (heparin-induced thrombocytopenia): immune (PF4-heparin antibodies) → thrombocytopenia + paradoxical thrombosis; typically day 5–10 (earlier with prior exposure).
Heparin resistance (common in CPB): failure to achieve target ACT despite adequate dosing.
- Causes: AT deficiency (consumption, sepsis, liver disease), high heparin-binding proteins (inflammation), prior heparin exposure, thrombocytosis, high factor VIII.
- Management: confirm dose/line; check ACT device; give additional heparin; consider AT concentrate (or FFP if AT concentrate unavailable) to restore response.

Low molecular weight heparin (LMWH) and fondaparinux (contrast points)

LMWH: shorter chains → relatively more anti-Xa than anti-IIa; more predictable PK; renal clearance.
Monitoring usually not required; if needed: anti-Xa (not aPTT/ACT).
Reversal: protamine partially reverses LMWH (better for anti-IIa than anti-Xa activity); may require repeat dosing; incomplete reversal expected.
Fondaparinux: synthetic pentasaccharide, indirect Xa inhibitor via AT; no reliable protamine reversal.

Protamine sulfate

What it is: strongly basic (cationic) polypeptide (traditionally from salmon sperm; also recombinant sources) that binds anionic heparin → inactive stable complex.
Onset/duration: rapid onset (minutes). Protamine half-life ~7–10 min; heparin–protamine complex cleared by RES. Risk of heparin rebound after large heparin doses/CPB due to redistribution of heparin from tissues.
Dosing (UFH reversal)
- Rule of thumb: 1 mg protamine neutralises ~100 units UFH remaining in circulation.
- Calculate from: total heparin given minus estimated clearance over time; or use heparin concentration/protamine titration devices.
- Administration: slow IV (e.g. over 10–20 min in cardiac practice) to reduce adverse reactions; avoid rapid bolus.
Excess protamine is anticoagulant: impairs platelet function, interferes with fibrin polymerisation, can prolong ACT/aPTT and worsen bleeding.
Adverse reactions (high-yield)
- Systemic hypotension (histamine release, vasodilation) esp. rapid administration.
- Anaphylaxis/anaphylactoid reactions.
- Pulmonary vasoconstriction / acute pulmonary hypertension → RV failure, hypoxaemia; can be catastrophic (rare).
- Bradycardia, bronchospasm; complement activation; platelet activation in some settings.
Risk factors for severe protamine reaction
- Previous protamine exposure (e.g. prior cardiac surgery).
- NPH insulin use (protamine-containing insulin) → sensitisation.
- Fish allergy (classically cited; true predictive value variable).
- History of vasectomy/infertility (antiprotamine antibodies described; association debated).

Managing bleeding after heparin reversal (structured approach)

1) Surgical causes: check field, anastomoses, graft suture lines, cannulation sites; consider re-exploration early if brisk bleeding.
2) Residual heparin / rebound
- Check ACT (and/or heparin concentration/anti-Xa if available).
- If residual heparin suspected: give additional small aliquots of protamine guided by tests; avoid large empiric doses (risk protamine anticoagulation).
3) Coagulopathy (common after CPB/major haemorrhage)
- Hypothermia, acidosis, haemodilution; platelet dysfunction/thrombocytopenia; low fibrinogen; factor deficiency; hyperfibrinolysis.
- Use viscoelastic testing (TEG/ROTEM) if available to target: fibrinogen (cryoprecipitate/fibrinogen concentrate), platelets, plasma/PCC, antifibrinolytic (TXA).
4) Drug effects: antiplatelets (aspirin, P2Y12 inhibitors), DOACs, residual heparin from lines/flushes, excessive protamine.

Special situations

HIT and urgent surgery/CPB
- Avoid heparin if HIT (or strongly suspected). Use alternative anticoagulant (institutional protocols; commonly bivalirudin for CPB where expertise exists).
- Protamine does not treat HIT; platelet transfusion generally avoided unless life-threatening bleeding or urgent surgery with severe thrombocytopenia (specialist advice).
Neuraxial/regional anaesthesia considerations (exam-relevant principles)
- Systemic anticoagulation increases risk of spinal/epidural haematoma; follow national guidance (e.g. ASRA/ESAIC/AoA) for timing with UFH/LMWH and catheter management.
- If unexpected full heparinisation occurs with neuraxial catheter in situ: urgent senior review, neurological monitoring, clear plan for catheter removal timing and reversal strategy.

Explain the mechanism of action of unfractionated heparin and why antithrombin matters.

Aim: describe mechanism + clinical implications (heparin resistance, monitoring).

UFH binds antithrombin (AT) causing a conformational change that greatly accelerates AT inhibition of activated clotting factors.
Main targets: thrombin (IIa) and factor Xa (also IXa, XIa, XIIa).
To inhibit thrombin, heparin chain must be long enough to bridge AT and thrombin (hence LMWH has less anti-IIa).
If AT is low (consumption, liver disease, sepsis), heparin effect is reduced → heparin resistance; treat with AT concentrate/FFP.

How do you monitor high-dose heparin during cardiopulmonary bypass? What are the limitations of ACT?

Aim: name ACT and discuss confounders; mention alternatives.

Standard bedside test: ACT pre-heparin baseline then after bolus; maintain above institutional target during CPB.
ACT limitations: affected by hypothermia, haemodilution, thrombocytopenia/platelet dysfunction, factor deficiency, and device variability; not a pure measure of heparin concentration.
Alternatives/adjuncts: heparin concentration assays (protamine titration systems), anti-Xa (less practical intraop), viscoelastic tests for global haemostasis (not heparin dose).

Define heparin resistance and outline a practical management plan in theatre.

Aim: definition + causes + stepwise management.

Definition (pragmatic): failure to achieve target ACT after an adequate heparin dose (e.g. for CPB).
Immediate checks: confirm dose calculation, IV access/line patency, sampling/ACT machine error, baseline ACT.
Give additional heparin while reassessing ACT response.
Consider AT deficiency: treat with AT concentrate (preferred) or FFP if concentrate unavailable; then recheck ACT.
If persistent: discuss alternative anticoagulation strategy with surgical/perfusion team (specialist protocols).

Describe protamine: mechanism, onset/duration, and how you would calculate a dose to reverse heparin.

Aim: binding mechanism + dosing rule + practical administration.

Protamine is a cationic polypeptide that binds anionic heparin forming an inactive complex.
Onset within minutes; short half-life (~7–10 min). Be aware of heparin rebound after CPB/large doses.
Dose: 1 mg protamine ≈ 100 units UFH remaining; estimate remaining heparin from total dose and time elapsed, or use heparin concentration/protamine titration systems.
Give slowly IV (e.g. over 10–20 min) with close haemodynamic monitoring.

What are the important adverse effects of protamine and how do you manage a severe reaction?

Aim: list reactions + immediate management including RV failure/pulmonary HTN scenario.

Adverse effects: systemic hypotension (esp rapid bolus), anaphylaxis/anaphylactoid, acute pulmonary hypertension → RV failure, bronchospasm, bradycardia.
Immediate actions: stop/slow protamine; call for help; 100% O2; secure airway/ventilation; treat as anaphylaxis if suspected (adrenaline, fluids, vasopressors).
If pulmonary hypertensive crisis/RV failure: optimise oxygenation/ventilation, correct acidosis, consider pulmonary vasodilators (e.g. inhaled nitric oxide/prostacyclin where available), inotropes (e.g. adrenaline/dobutamine), vasopressors to maintain coronary perfusion.
Consider returning to CPB/ECMO in cardiac setting if refractory collapse (team decision).

List risk factors for protamine reactions and how this changes your plan.

Aim: identify high-risk patients and mitigation steps.

Risk factors: prior protamine exposure, NPH insulin use, fish allergy (association variable), possibly vasectomy/infertility (antibodies described).
Plan: discuss risk with team; ensure resuscitation drugs ready; administer slowly with invasive monitoring; consider test dose only if local policy (not reliably predictive).
Have strategy for managing pulmonary hypertensive response (RV support, pulmonary vasodilators if available).

A patient continues to bleed after protamine at the end of CPB. How do you structure your assessment and management?

Aim: systematic approach: surgical vs coagulopathy vs residual heparin vs protamine excess.

Assess haemodynamics, temperature, acid-base, calcium; quantify bleeding and communicate with surgeon.
Check for surgical bleeding (field inspection, cannulation sites, graft lines); low threshold for re-exploration if brisk.
Check ACT/heparin concentration for residual heparin/rebound; if elevated, give small additional protamine aliquots guided by tests.
Treat coagulopathy using viscoelastic testing if available: fibrinogen replacement, platelets, plasma/PCC, TXA if hyperfibrinolysis; correct hypothermia/acidosis.
Consider protamine excess if ACT prolonged but heparin level low and bleeding persists; avoid further protamine; manage with blood products/supportive care.

How does protamine reverse LMWH and what are the limitations?

Aim: partial reversal and practical implications.

Protamine binds LMWH but incompletely reverses anti-Xa activity; better reversal of anti-IIa component.
May require repeat dosing depending on timing and bleeding severity; expect residual anticoagulant effect.
For fondaparinux there is no reliable protamine reversal.

Explain heparin-induced thrombocytopenia (HIT): pathophysiology, presentation, and immediate management principles perioperatively.

Aim: immune mechanism + thrombosis risk + stop heparin and use alternative anticoagulant.

Immune-mediated antibodies against PF4–heparin complexes activate platelets → thrombocytopenia and prothrombotic state.
Timing: typically day 5–10 after exposure (earlier if recent prior exposure). Look for platelet fall >50% and new thrombosis/skin necrosis.
Immediate management: stop all heparin (including flushes); send HIT testing; start non-heparin anticoagulant per protocol (e.g. argatroban/bivalirudin/danaparoid depending on setting).
Avoid warfarin until platelets recover; involve haematology/cardiac anaesthesia/perfusion early if surgery urgent.

What is 'heparin rebound' and how can it present after cardiac surgery?

Aim: redistribution phenomenon + management.

After protamine, heparin can redistribute from extravascular/tissue binding sites back into plasma, especially after large doses/CPB.
Presentation: delayed bleeding with rising ACT/heparin assay after initially adequate reversal.
Management: recheck coagulation (ACT/heparin concentration); give additional small protamine doses guided by results; avoid overcorrection; treat coagulopathy concurrently.